Type I hypersensitivity reactions (HSR) to dabrafenib are rare but have been previously described. We present a case where a 72-year-old woman with recurrent, metastatic BRAF-mutated melanoma developed a type I HSR to dabrafenib. We, therefore, developed a desensitization protocol with encorafenib, a similar class agent, to allow the patient to continue with treatment. Patients with a history of HSR to dabrafenib may be considered for encorafenib desensitization when other therapeutic options are limited.
|Original language||English (US)|
|Number of pages||3|
|State||Accepted/In press - 2021|
- B-raf (BRAF)
- Hypersensitivity reaction
ASJC Scopus subject areas
- Cancer Research